<DOC>
	<DOCNO>NCT02686593</DOCNO>
	<brief_summary>The study aim evaluate efficacy regimen CLAM relapse refractory AML use first salvage patient relapse fail standard treatment daunorubicin/cytarabine induction .</brief_summary>
	<brief_title>Clofarabine , Cytarabine Mitoxantrone ( CLAM ) Relapsed Refractory AML</brief_title>
	<detailed_description>Clofarabine , second generation purine nucleoside analog , evaluate several study relapse AML . [ 1-3 ] Safety dosages clorafabine already determine previous phase I/II study . A demonstrable complete remission rate 40 % 50 % show relapsed refractory AML . [ 4-6 ] Since 2009 , Clofarabine ( 40mg/m2/day 5 day ) combination high-dose cytarabine ( 2g/m2/day 5 day ) ( CLARA ) adopt re-induction protocol relapse refractory patient AML Department Medicine , Queen Mary Hospital . We show protocol safe , tolerable effective relapse AML . A recent updated analysis ( Gill H et al. , unpublished ) show complete response rate 50.8 % . With CLARA regimen , patient ( N=60 ) develop grade 3/4 neutropenia thrombocytopenia . 8 % develop grade 3/4 hepatotoxicity 40 % develop febrile neutropenia clinical sepsis . There increase evidence show clofarabine safe efficacious combine anthracyclines idarubicin daunorubicin.7,8 In prospective study , combine clofarabine cytarabine ( Ara-C ) topoisomerase II inhibitor mitoxantrone . In protocol , dosages clofarabine cytarabine reduce 30mg/m2/day 750mg/m2/day respectively , comparable clinical trial . In previous publication experience use CLARA Tse et al Leung et al , clofarabine 40mg/m2/day 5 day combine high-dose cytarabine 2g/m2/day . [ 5,6 ] The regimen show safe . The combination clofarabine anthracyclines evaluate . Mathiesen al evaluate CIA regimen comprise clofarabine 20mg/m2/day day 1 day 5 , idarubicin 10mg/m2/day day 1 day 3 cytarabine 1g/m2/day day 1 day 5 . [ 7 ] Abbie et al investigate regimen comprise Clofarabine 20mg/m2/day 25mg/m2/day 5 day combination mitoxantrone etoposide.7 Based clinical trial extensive experience use CLARA , dosages clofarabine CLAM determine . With significant reduction dose cytarabine 750mg/m2/day 5 day CLAM , dose clofarabine choose 30mg/m2/day 5 day aim maintain efficacy see CLARA . The aim combination maintain improve treatment efficacy see low treatment-related toxicity via dose reduction clofarabine cytarabine compare CLARA . CLAM expect safe tolerable especially use first salvage patient ECOG performance status 0 1 . The regimen CLAM approve institutional review board Queen Mary Hospital/University Hong Kong . In pilot study , 4 patient use regimen . 2 patient achieve complete remission . Cardiotoxicity see . Grade 3/4 hepatotoxicity see . There treatment-related mortality observe . CLAM show safe manageable toxicity profile . In addition , less myeloid toxicity expect consolidation patient achieve remission well marrow reserve compare relapse . Patients cardiac , liver renal function performance status evaluate continuously patient cardiac dysfunction , significantly impaired renal liver function ECOG performance status 2 exclude . Thus consolidation dose induction expect safe tolerable . The study aim evaluate efficacy regimen CLAM relapse refractory AML use first salvage patient relapse fail standard treatment daunorubicin/cytarabine induction . We aim improve treatment efficacy tolerable dose clofarabine cytarabine compare CLARA .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>1 . Relapsed refractory acute myeloid leukemia ( AML ) one firstline chemotherapy regimen 2 . Patients age 18 65 inclusively 3 . European Cooperative Oncology Group ( ECOG ) performance status less 2 1 . Patients age less 18 65 2 . ECOG performance status 2 3 . Acute promyelocytic leukaemia 4 . Uncontrolled active infection 5 . Uncontrolled arrhythmia 6 . Altered renal dysfunction serum creatinine &gt; 1.5 x ULN and/or creatinine clearance &lt; 50 mL/min 7 . Significant neurologic ( grade &gt; 2 ) psychiatric disorder , dementia seizure 8 . Clinical symptom suggest active central nervous system leukemia 9 . Severe complication leukemia uncontrolled bleeding , pneumonia hypoxia shock disseminate intravascular coagulation 10 . Patients know HIV , Hepatitis B C infection history cirrhosis 11 . Patients Significant hepatic dysfunction : Direct bilirubin &gt; 1.5 x upper limit normal ( ULN ) age ; ALT AST &gt; 3 x upper limit normal ( ULN ) age ; Lipase &gt; 2.0 x upper limit normal ( ULN ) age 12 . Females childbearing potential must negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Clofarabine</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
</DOC>